These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28887314)

  • 1. Novo Nordisk pays $58.7m to settle claims of mis-selling liraglutide.
    Dyer O
    BMJ; 2017 Sep; 358():j4214. PubMed ID: 28887314
    [No Abstract]   [Full Text] [Related]  

  • 2. Pfizer settles largest ever fraud suit for off-label promotion.
    Ratner M
    Nat Biotechnol; 2009 Nov; 27(11):961-2. PubMed ID: 19898429
    [No Abstract]   [Full Text] [Related]  

  • 3. The limits of free speech.
    Nature; 2012 Dec; 492(7429):311. PubMed ID: 23281497
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting drug companies' bottom line.
    Prescrire Int; 2011 Jan; 20(112):25. PubMed ID: 21462792
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA regulation of off-label drug promotion under attack.
    Kesselheim AS; Mello MM; Avorn J
    JAMA; 2013 Feb; 309(5):445-6. PubMed ID: 23385267
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bitter pills for drug companies.
    Newman M
    BMJ; 2010 Sep; 341():c5095. PubMed ID: 20851842
    [No Abstract]   [Full Text] [Related]  

  • 8. Company pays over $81m for allegedly promoting topiramate for unapproved uses.
    Kmietowicz Z
    BMJ; 2010 May; 340():c2848. PubMed ID: 20508021
    [No Abstract]   [Full Text] [Related]  

  • 9. Resident and fellow section. Conflicts of interest between physicians and the pharmaceutical industry: focus on headache medicine.
    Rubin EB; Bernat JL
    Headache; 2008; 48(10):1545-9. PubMed ID: 19076654
    [No Abstract]   [Full Text] [Related]  

  • 10. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Merck pays $1bn penalty in relation to promotion of rofecoxib.
    Tanne JH
    BMJ; 2011 Nov; 343():d7702. PubMed ID: 22123916
    [No Abstract]   [Full Text] [Related]  

  • 12. Truth, Falsity, and Fraud: Off-Label Drug Settlements and the Future of the Civil False Claims Act.
    Krause JH
    Food Drug Law J; 2016; 71(3):401-40. PubMed ID: 29140064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novo sets sights on obesity market with diabetes drug.
    Sheridan C
    Nat Biotechnol; 2014 Nov; 32(11):1071-2. PubMed ID: 25380424
    [No Abstract]   [Full Text] [Related]  

  • 14. Medical executives face criminal charges for "misbranded" devices.
    Lenzer J
    BMJ; 2016 Jun; 353():i3270. PubMed ID: 27287054
    [No Abstract]   [Full Text] [Related]  

  • 15. [The antidiabetic drug liraglutide lowers risk of cardiac death].
    Overbeck P
    MMW Fortschr Med; 2016 Jun; 158(12):14. PubMed ID: 27323977
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical trial transparency--antidote to weaker off-label-promotion rules?
    Outterson K
    N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
    [No Abstract]   [Full Text] [Related]  

  • 17. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
    Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
    J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 diabetes market.
    Gershell L
    Nat Rev Drug Discov; 2005 May; 4(5):367-8. PubMed ID: 15902771
    [No Abstract]   [Full Text] [Related]  

  • 20. Can I tell you the truth? A comparative perspective on regulating off-label scientific and medical information.
    Osborn JE
    Yale J Health Policy Law Ethics; 2010; 10(2):299-356. PubMed ID: 20681438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.